Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $25.33 and traded as high as $25.37. Amplify Weight Loss Drug & Treatment ETF shares last traded at $25.36, with a volume of 850 shares traded.
Amplify Weight Loss Drug & Treatment ETF Trading Up 2.6%
The firm has a market capitalization of $5.83 million, a PE ratio of 24.31 and a beta of 0.42. The business’s 50 day simple moving average is $25.59 and its two-hundred day simple moving average is $25.33.
About Amplify Weight Loss Drug & Treatment ETF
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Recommended Stories
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
